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Background: Glioblastoma is the most common type of primary brain tumors. Cisplatin is a commonly used
chemotherapeutic agent for Glioblastoma patients. Despite a consistent rate of initial responses, cisplatin treatment
often develops chemoresistance, leading to therapeutic failure. Cellular resistance to cisplatin is of great concern
and understanding the molecular mechanisms is an utter need.
Methods: Glioblastoma cell line U251 cells were exposed to increasing doses of cisplatin for 6 months to establish
cisplatin-resistant cell line U251R. The differential miRNA expression profiles in U251 and U251R cell lines were
identified by microarray analysis and confirmed by Q-PCR. MiRNA mimics were transfected into U251R cells, and
cellular response to cisplatin-induced apoptosis and cell cycle distribution were examined by FACS analysis.
Results: U251R cells showed 3.1-fold increase in cisplatin resistance compared to its parental U251 cells. Microarray
analysis identified Let-7b and other miRNAs significantly down-regulated in U251R cells compared to U251 cells.
Transfection of Let-7b mimics greatly re-sensitized U251R cells to cisplatin, while transfection of other miRNAs has
no effect or slightly effect. Cyclin D1 is predicted as a target of Let-7b through bioinformatics analysis. Over-
expression of Let-7b mimics suppressed cyclin D1 protein expression and inhibited cyclin D1-3’-UTR luciferase
activity. Knockdown of cyclin D1 expression significantly increased cisplatin-induced G1 arrest and apoptosis.
Conclusions: Collectively, our results indicated that cisplatin treatment leads to Let-7b suppression, which in turn
up-regulates cyclin D1 expression. Let-7b may serve as a marker of cisplatin resistance, and can enhance the
therapeutic benefit of cisplatin in glioblastoma cells.
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Glioma is the first commonly diagnosed types of intra-
cranial tumors, accounting for more than 50% among all
primary brain tumors [1]. Gliomas can be classified as
astrocytomas, oligodendrogliomas, or tumors with mor-
phological features of both two types of tumors above.
According to their degrees of malignancy, gliomas are
classified from graded I to IV. Glioblastoma, one subtype
of aggressive gliomas, is the most common and lethal
brain tumor, with widespread invasion in brain, poor* Correspondence: fenghuachen2013@sina.cn
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reproduction in any medium, provided the ordifferentiation, destruction of normal brain tissue, and
resistance to traditional therapeutic approaches [1-3].
Current options for treatment of glioblastoma include
surgical resection of the primary tumor to reduce the
tumor size, followed by radiotherapy and adjuvant chemo-
therapy with temozolomide (TMZ) [4]. However, even
with successful surgical resection and subsequent radio-
therapy and chemotherapy, the prognosis remains poor,
with a median survival of 12–15 months [5]. High tumor
recurrence rate and mortality of patients is due to incom-
plete removal of primary tumors after surgery and resist-
ance to chemotherapy. The infiltrating characteristics of
glioblastoma make complete removal of primary tumor
virtually impossible, and even cause normal brain tissue
damage. Therefore, the limitation of current options for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quired to study mechanism of chemoresistance regulation
of this cancer.
MicroRNAs (miRNAs), a class of 22-nucleotide small
non-coding RNAs, can regulate gene expression at post-
transcriptional level. MiRNAs are evolutionarily con-
served and negatively regulate gene expression. They are
transcribed by RNA polymerase II, spliced, and then
poly-adenylated to generate primitive miRNAs (pri-
miRNAs) [6]. The stem-loop structure of pri-miRNAs
can be recognized and cleaved by the nuclear RNase III
Drosha to generate hairpin precursor miRNAs (pre-
miRNAs). Pre-miRNAs are rapidly exported to the cyto-
plasm by exportin-5, excised by the cytoplasmic RNase
III Dicer to generate a 22-nucleotide miRNA duplex:
one strand is a mature miRNA, whereas the other strand
(miRNA*) is normally unstable and degraded. The mature
miRNAs can suppress target gene expression by inter-
action with complementary sequences in the 3′-untrans-
lated regions (3′-UTRs) of target mRNAs and trigger
translation blockade or mRNA degradation depending on
whether it is completely or partially matched with the tar-
get genes [7]. Multiple studies have shown that miRNAs
are deregulated in various types of human cancers [8],
including glioblastoma [9-11], breast cancer [12], lung
cancer [13], colon cancer [14], and ovarian cancer [15].
MiRNAs may function as oncogenes or tumor suppres-
sors, and also involve in chemoresistance [15,16].
Cisplatin has dramatically been used as the first line
treatment for several types of solid tumors, such as
breast, head and neck, ovarian, and lung cancers [17].
Cisplatin in combination with temozolomide has been in
clinical trial in malignant glioma patients [18-20]. The
combination of temozolomide and cisplatin is safe and
effective in the treatment of chemotherapy-naïve GBM
patients, and also in pre-treated patients with high-
grade glioma refractory to single-agent temozolomide
[21,22]. However, cancer cells can develop a resistant
phenotype to cisplatin in many patient cases with very
poor clinical outcomes [23]. Mechanisms associated
with chemoresistance to cisplatin have been investi-
gated, such as up-regulation of drug transporter pro-
teins, aberrancies in DNA damage repair, and apoptosis
induction [24]. However, mechanisms of how tumors
become resistant to cisplatin have still not been clearly
established [25].
To study chemoresistance in glioma, we established a
cisplatin-resistant glioblastoma cell line U251R, which is
3.1 fold resistant to cisplatin compared to its parental cell
U251. MiRNA expression signature analyzed by micro-
array identified 16 miRNAs as down-regulated in U251R.
Let-7b is one of the most significantly suppressed miRNA.
Furthermore, over-expression of Let-7b significantly re-
sensitized U251R cells to cisplatin through inhibition ofcyclin D1 expression. Cyclin D1 knockdown dramatically
increased cisplatin-induced apoptosis and G1 arrest.
Taken together, our results suggested that cisplatin treat-
ment leads to Let-7b suppression, which in turn up-
regulates cyclin D1 expression, resulting in resistance to
cisplatin. Therefore, Let-7b may be considered as a marker
for early diagnosis of cisplatin resistance, and restoration
of Let-7 in glioblastoma could be a new strategy for
cisplatin-resistant cancer treatment in the future.
Materials and methods
Reagents, antibodies, and vectors
Fetal bovine serum for cell culture and Lipofectamine
2000 were purchased from Invitrogen (Carlsbad, CA,
USA). Anti-β-actin antibody was from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Anti-Bcl-2, Bax, and
ppRb antibodies were from Cell Signaling Technology
(Danvers, MA, USA). Anti-cyclin D1 antibody was from
Abcam (Cambridge, MA, USA). Let-7b mimics expres-
sion vector was purchased from Wuhan Genesil Bio-
technology (Wuhan, Hubei, China).
Cell culture
Human neuronal glioblastoma cell line U251 was a gift
from Dr. Zhongping Chen (Sun Yat-Sen University,
Guangzhou, Guangdong, China). U251 cell line was
maintained in Dulbecco’s Modified Eagle’s Medium
(Sigma, St. Louis, MO) supplemented with 10% fetal
bovine serum (Invitrogen), 100 units/mL penicillin and
100 μg/mL streptomycin (Invitrogen), in a 5% CO2 hu-
midified atmosphere at 37°C.
Generation of cisplatin-resistant U251 cells in vitro
To generate a cisplatin-resistant cell line, U251 cells
were exposed to increasing concentrations of cisplatin.
Cisplatin concentrations were increased stepwise from
0.1 μg/mL to 0.5 μg/mL when the cells resumed growth
kinetics similar to the untreated parental cells. Cells
with the ability to grow in 0.5 μg/mL of cisplatin were
obtained 4 months after the initial drug exposure,
named as U251R.
Cell viability
Cell lines were seeded into 96-well plates at a density of
5 × 103 cells/100 μL medium per well. After adherence,
cells were treated with various concentrations of cis-
platin for 48 h, with DMSO as negative controls. At the
end of treatment, the tetrazolium compound, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT, Sigma) was added and then incubated for add-
itional 4 h at 37°C in the dark. The formazan crystals
were dissolved by DMSO, and the absorbance was
recorded using an ELISA plate reader.
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Cyclin D1 shRNA (cyclin-sh) and negative scramble
shRNA (SCR) were inserted into pGPHI vector. The





SCR, forward primer 5-CACCGTTCTCCGAACGTGT
CACGTCAAGAGATTACGTGACACGTTCGGAGAAT
TTTTTG-3, and reverse primer 5-GATCCAAAAAA
TTCTCCGAACGTGTCACGTAATCTCTTGACGTGA
CACGTTCGGAGAAC-3. Cyclin D1 3’-UTR sequence
was cloned into pGL3-Luc vector. The primers were as
follows: forward primer 5-GCTCTAGAGCTGACTCC
AAATCTCAATGAAGCCA-3, and reverse primer 5-GC
TCTAGAGCTAACCAGAAATGCACAGACCCAG-3.MiRNA microarray analysis
Total RNA was extracted from each cell line using TRIzol
reagent (Invitrogen) according to the manufacturer's in-
structions. The RNA samples were submitted to KangChen
Bio-tech (Shanghai, China), then labeled with Hy3™
fluorescent dye for hybridization on a miRCURY™ LNA
microRNA array (Exiqon, Vedbaek, Denmark). Expres-
sion levels of selected miRNAs differed by at least 2-fold
between cisplatin-resistant U251R cell line and parental
U251 cell line.Immunoblot analysis
Cell lysates were loaded onto 10% SDS–polyacrylamide
gels, electrophoresed and transferred to PVDF mem-
branes (Millipore, Billerica, MA, USA). Membranes
were blocked in TBS-Tween-20 containing 5% non-fat
milk at room temperature for 1 h and then incubated
with primary antibodies at 4°C overnight. On the second
day, the blots were incubated with HRP-linked second-
ary antibodies at room temperature for 1 h. After three
times’ wash in TBST buffer, the blots were visualized by
ECL Reagent (Cell Signaling Technology) as previously
described [26].Luciferase reporter assay
This assay was performed as previously described [27].
Briefly, cells were seeded in a 24-well plate and transfected
with miRNA mimics expression vectors, additional pGL3-
Luc/cyclin D1-3’-UTR plasmid, and pRL-TK plasmid.
Twenty-four hours after transfection, cells were lysed
and then luciferase activities were measured according
to the manufacturer’s protocol (Promega, Madison, WI,
USA). Each sample’s luciferase activity was normalized
to that of renilla.MiRNA qRT-PCR detection and quantification
Total RNA was isolated from tissues using Trizol
(Invitrogen) following the manufacturer’s instructions.
RNA was converted to cDNA with Reverse Transcription
System (Promega) according to the manufacturer’s in-
structions. Q-PCR was performed using the miRNA SYBR
Real-time PCR kit (Guangzhou RiboBio, Guangzhou,
Guangdong, China) on the ABI 7300 Real-Time PCR sys-
tem (Life Technologies, Grand Island, NY). To calculate
relative expression, the (ΔΔCT) method was used in com-
paring miRNA expression in U251R cells to U251 parental
cancer cells according to ABI’s protocol.
Annexin V-FITC apoptosis detection
This assay was performed according to the manufac-
turer’s instructions (Beyotime Institute of Biotechnology,
Shanghai, China). Briefly, after treatment, cells were col-
lected, washed with PBS and pelleted. Cell pellets were
resuspended in 100 μL of Annexin V-FITC labeling solu-
tion and incubated at room temperature in dark for 30
minutes. After incubation, reaction was stopped by adding
300 μL ice-cold PBS and measured on FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ).
Caspase-3 activity analysis
Caspase-3 activity was measured by Caspase-Glo3/7 assay
kit (Promega) according to the manufacturer’s instructions.
Cell cycle analysis
This assay was performed as previously described [28].
Briefly, cells were harvested, washed twice with cold PBS
and fixed with 70% cold ethanol overnight. Fixative was
discarded and 0.2% Triton X-100 was added to the fixed
cells. Cells were washed with PBS again and resuspended
in PBS containing 50 mg/mL PI and 1 mg/mL RNase A
for 30 min in the dark on ice. The samples were then
analyzed on a flow cytometer.
Statistics
The Student′s t-test was used to compare the difference
between two tested groups. A value of p < 0.05 was con-
sidered as indicating a significant difference.
Results
Characterization of the induced cisplatin-resistant U251
cells
We observed no apparent difference in morphology or
growth rate between the parental U251 cells and cisplatin-
resistant U251 cells (hereafter refers as U251R). To com-
pare the sensitivity of the parental U251 and U251R cells
to cisplatin, cells were treated with different concentra-
tions of cisplatin for 72 hours and dose–response curves
were plotted as shown in Figure 1A. Dose-dependent
anti-proliferative activity were observed in both cell
Figure 1 Characterization of the induced cisplatin-resistant U251 cells. (A) U251 and U251R cells were treated with indicated concentration
of cisplatin for 72 hours and cell viability was tested by MTT. (B) IC50 of cisplatin in U251 and U251R cells was calculated.
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3.1 fold higher than that of the parental U251 cells, as
measured by the IC50 values for cisplatin over 48 hours
treatment: 1.4±0.1 μg/mL and 4.4±0.9 μg/mL, respect-
ively (Figure 1B).
Differential MiRNA expression profiles in U251 and U251R
cell lines identified by microarray analysis
Dysregulation of miRNA expression has been reported
to be associated with chemoresistance of human cancers.
Herein, we performed microRNA microarray containing
3100 probes to analyze differential miRNA expression
profiles in U251 and U251R cell lines. As shown in
Figure 2A, 23 miRNAs are up-regulated and 16 miRNAs
are down-regulated in U251R cells.
The microarray results were then validated by real-
time PCR. Consistent with microarray data, miR-182
and miR-224 were up-regulated in U251R cells; Let-7b,
miR-125b, miR-107 and miR-203 were significantly
suppressed in U251R cells (Figure 2B-G).
Re-sensitization of the resistant cells by transfection of
Let-7b
To investigate whether down-regulation of these miRNAs
in U251R cells involved in cisplatin resistance, miRNA
mimics were transfected into U251R cells, and then their
IC50 to cisplatin was determined. Interestingly, compared
with negative control transfection, transfection of Let-7b
greatly sensitized U251R cells to cisplatin, with IC50 de-
creased from 4.38±0.56 μg/mL to 1.62±0.03 μg/mL, which
is similar to that of U251 parental cells (1.44±0.11 μg/mL)
(Figure 3A). Notably, transfection of neither miR-125b
mimics nor miR-107 mimics has significant effect on the
sensitivity of U251R cells to cisplatin. MiR-203 mimics
lead to moderate inhibition of cisplatin sensitivity. The
dose response curves of U251R cells transfected withLet-7b mimics or Scramble to cisplatin were shown in
Figure 3B. These results suggested that Let-7b plays a
critical role in cisplatin resistance, and transfection of
Let-7b re-sensitized the U251R cells to cisplatin.
Transfection of Let-7b increased cisplatin-induced G1
arrest and apoptosis in U251R cells
To further confirm the role of Let-7b in cisplatin resist-
ance, cell cycle distribution was analyzed by flow cytom-
etry. Compared with negative control, transfection of
Let-7b mimics into U251R cells significantly increased
cisplatin-induced G1 arrest (Figure 4A-C).
The cisplatin-induced apoptosis was examined by
Annexin V/PI staining (Figure 5A-C). Consistently, Let-7b
mimics increased cisplatin-induced apoptosis in U251R
cells compared with scramble transfection (16.66±1.57%
Vs. 8.32±0.85%, p < 0.05). Notably, the apoptosis in
U251R transfected with Let-7b is comparable to that in
U251 parental cells (16.66±1.57% vs. 17.82±1.47%, p > 0.05)
(Figure 5D).
The caspase-3 activity was determined. After 0.625 μg/
mL cisplatin treatment for 48 hours, caspase-3 activity
was significantly increased in U251 cells, but less in-
creased in U251R cells. Interestingly, compared with
scramble transfection, cisplatin-induced caspase-3 activity
in U251R cells was partially enhanced by transfection of
Let-7b mimics (3.92±0.08 vs. 6.23±0.30, p < 0.05). In fact,
the activity of caspase-3 in U251R-Let-7b cells is similar
to U251 parental cells (6.23±0.30 vs. 5.9±0.34, p > 0.05)
(Figure 5E). Taken together, these results suggested that
over-expression of Let-7b reversed the resistance to cis-
platin in U251R cells.
Cyclin D1 acts as a downstream target of Let-7b
To clarify the mechanism of Let-7b-induced changes in
chemosensitivity, we first used miRBase and TargetScan
Figure 2 Differential miRNA expression profiles in U251 and U251R cell lines. (A) MiRNA expression signature was analyzed by miRNA
microarray. (B-G) Selected miRNAs were confirmed by real-time PCR.
Figure 3 Transfection of Let-7b re-sensitization of the resistant cells. (A) U251R cells were transfected with mimics of miR-107, miR-125b,
miR-203, Let-7b or scramble (SCR). Then their IC50 to cisplatin was determined. U251 parental cells were used as control. (B) U251R cells were
transfected with Let-7b mimics or scramble (SCR), and then the dose–response curves were plotted.
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Figure 4 Let-7b increased cisplatin induced G0/G1 arrest. U251R cells were transfected with scramble (SCR) (A) or Let-7b mimics (B) and
then treated with cisplatin; cell cycle was detected by flow cytometry. The percentage of cells in different cell cycle phases was calculated (C).
Data is presented from three independent experiments, and the symbol * indicates statistical difference (p < 0.05).
Figure 5 Transfection of Let-7b increased cisplatin-induced apoptosis in U251R cells. U251 cells (A), U251R cells (B) or U251R cells
transfected with Let-7b (C) were treated with cisplatin at 0.625 μg/mL for 48 hours. Cisplatin-induced apoptosis was assessed by Annexin V
staining followed by flow cytometry. Right-hand quadrants indicate Annexin V positive cells, indicative of apoptosis. (D) The percentage of
apoptotic cells was calculated from at least three separate experiments. (E) U251, U251R and U251R transfected with Let-7b mimics were treated
with cisplatin for 48 hours, and caspase-3 activity was measured. The results were presented as mean±SD (n = 3) (*p < 0.05).
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Figure 6 Let-7b regulated cyclin D1 expression. (A) Prediction of Let-7b binding site in cyclin D1 3’-UTR by TargetScan. (B) U251 and U251R
cells were transfected with Let-7b mimics or with scramble mimics (SCR). Then cisplatin expression was detected by western blot. (C) The cyclin
D1-3′-UTR luciferase construct was co-transfected into U251 cells with indicated concentration of Let-7b mimics or with a scramble mimics (SCR)
as negative control. Each sample’s luciferase activity was normalized to that of renilla, and results were expressed as mean±SD (n = 3) (*p < 0.05).
Figure 7 Knockdown of cyclin D1 expression increased cisplatin
induced G1 arrest and apoptosis in U251R cells. (A) U251R cells
were transfected with shRNA against cyclin D1 or scramble (SCR),
and expression of cyclin D1 was validated by western blot. (B) Cells
were treated with cisplatin 0.625 μg/mL for 48 hours, then cell cycle
was detected by flow cytometry. (C) Cisplatin-induced apoptosis was
assessed by Annexin V staining followed by flow cytometry.
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binding site is found in 3'-UTR of cyclin D1 (Figure 6A).
To validate if cyclin D1 is a real target of Let-7b, Let-
7b mimics was transfected into U251 and U251R cells.
As shown in Figure 6B, transfection of Let-7b mimics
greatly inhibited cyclin D1 expression both in U251 cells
and U251R cells. To test if this is a direct regulation, 3'-
UTR of cyclin D1 was cloned into a luciferase expres-
sion vector. The data showed that Let-7b mimics
inhibited cyclin D1-3’-UTR luciferase activity in a dose-
dependent manner (Figure 6C). Overall, these results
suggested that Let-7b directly targets cyclin D1 and in-
hibits cyclin D1 expression.
Knockdown of cyclin D1 expression increased cisplatin-
induced G1 arrest and apoptosis
Amplification, mutation, and high expression of cyclin
D1 are reported to be associated with resistance to
chemotherapy and poor prognosis in breast tumors,
brain tumors and testicular germ cell tumors. To test if
cyclin D1 plays an important role in cisplatin resistance
in U251R cells, cyclin D1 expression was knockdown by
shRNA (Figure 7A). Cisplatin triggered G1 arrest was in-
creased by cyclin D1-shRNA (Figure 7B). Consistently,
the apoptosis induced by cisplatin was increased by cyc-
lin D1-shRNA (Figure 7C).
Discussion
Current anti-cancer chemotherapeutic agents for glio-
blastoma have not significantly improved the survival of
glioblastoma patients during the past ten years [16].
Those patients succumb to their disease mostly for the
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either inherent (intrinsic resistance), or induced by che-
motherapeutic drugs (acquired resistance) [29]. Intrinsic
resistance to anti-cancer drugs results from various fac-
tors, including somatic cell genetic diversification in tu-
mors and individual variations of patients. Acquired
drug resistance occurs when a tumor that initially
sensitive to an anti-cancer drug becomes resistant to
that treatment. One prevalent reason for acquisition of
chemoresistance is induction of energy-dependent trans-
porter proteins that pump anti-cancer drugs out of cells,
and other mechanisms of chemoresistance including re-
sistance to drug-induced apoptosis may also play an im-
portant role in acquired drug resistance. Furthermore,
recent study indicates that intrinsic and acquired resis-
tances have some similar profiles [30]. So far, there is no
effective strategy to overcome chemoresistance. More-
over, drug resistance can only be identified after long-
time treatment until now. Therefore, early diagnosis to
indicate drug resistance is essential for optimizing
therapeutic strategy, avoiding unnecessary treatment
and drug-induced side effects. In view of this fact, the
research on mechanisms of chemoresistance regulation,
the early diagnosis of drug resistance, and the develop-
ment of novel and effective anti-cancer therapies against
glioblastoma are urgently required. In this study, Let-7b
down-regulation is associated with acquired cisplatin
resistance in U251R cells. Let-7b mimics re-sensitized
U251R cells to cisplatin through suppression of cyclin
D1 protein expression. Based on these findings, Let-7b
might be considered as an early diagnostic marker of
cisplatin resistance, and restoration of Let-7b could
overcome cisplatin resistance in glioblastoma cells.
Recently, miRNA has been proved as one of the critical
regulators during glioma progression. Both up-regulation
and down-regulation of miRNAs are involved in the
development of glioblastomas and chemoresistance. Shi
et al. showed that over-expression of miR-21 could
attenuate TMZ-induced apoptosis in U87MG cells through
up-regulation of Bax, reduction of Bax/Bcl-2 ratio and
caspase-3 activity, demonstrated that miR-21 over-
expression is associated with resistance to chemotherapeu-
tic drug TMZ [31]. Furthermore, Li et al. demonstrated
that miRNA-21 targets LRRFIP1 which inhibits NF-κB
activation. NF-κB pathway is activated upon miR-21 over-
expression, exhibits significant anti-apoptotic efficacy, and
contributes to VM-26 resistance in glioblastoma [32].
Based on these findings, miR-21 could be a potential target
to increase the chemotherapeutic efficacy during glioblast-
oma treatment. Another study indicated that using an
established U251 cell line resistant to temozolomide,
Ujifuku et al. performed an analysis of miRNA expression
in this cell line and its parental cell line. Three miRNAs
miR-195, miR-455-3P, and miR-10a were identified as themost up-regulated miRNAs in the U251 cell line resistant
to temozolomide. Knockdown of miR-195 inhibited tumor
cell growth, suggesting that it could be a potential target
for treatment of glioblastoma with acquired TMZ resist-
ance [33]. In our study, Let-7b was down-regulated in
acquired cisplatin-resistant U251R cells. Furthermore, ec-
topic Let-7b can increase the sensitivity of U251R cells to
cisplatin through inhibition of cyclin D1 expression. In this
regard, Let-7b could overcome cisplatin resistance in glio-
blastoma cells, indicating that it could be applied to treat
glioblastoma patients with cisplatin resistance.
It is known that Let-7 modulates chemosensitivity in
various types of cancer. Let-7 inhibited gemcitabine
chemoresistance in pancreatic cancer [34], and could
also negatively modulate the chemoresistance in Head and
neck cancer [35]. Sugimura et al. showed that Let-7b and
Let-7c expression were down-regulated in cisplatin-
resistant esophageal cancer cell lines compared with their
parent cell lines [36]. Transfection of Let-7 into esopha-
geal cancer cell lines restored their sensitivity to cisplatin.
Furthermore, low expression of Let-7b and Let-7c in
before-treatment patients is correlated with poor response
to cisplatin-based chemotherapy, so Let-7 can also be used
as a marker to predict the sensitivity to cisplatin treatment
[36]. Moreover, Let-7b down-regulated cyclin D1 expres-
sion through targeting 3’-UTR of cyclin D1 mRNA, and
inhibited cell cycle progression in melanoma cells [37].
Let-7 also regulates cyclin D1 in other types of tumors. It
is reported that Let-7 miRNA inhibited cell growth par-
tially by decreasing mRNA expression of cell cycle stimu-
lators MYC and cyclin D1 in thyroid cancer [38]. Zhao
et al. demonstrated that Let-7b regulates neural stem cell
proliferation and differentiation by targeting cyclin D1
[39]. Our results also indicated that down-regulation of
Let-7b was correlated with cisplatin resistance in glioblast-
oma cells, and Let-7b could attenuate cyclin D1 expres-
sion then dampen chemoresistance of U251R cells to
cisplatin. Overall, restoration of Let-7 in glioblastoma may
offer a new approach for cancer treatment in the future.
Cyclin D1 belongs to a family of protein kinases that
involved in cell cycle regulation. Cyclin D1 has been
proved to be associated with chemoresistance to cisplatin-
based therapy. Noel et al. demonstrated that cyclin D1
expression was significantly higher in chemoresistant tes-
ticular germ tumor cell lines comparing with the parental
cells. Furthermore, cyclin D1 knockdown in combination
with cisplatin treatment inhibited tumor cell growth more
effectively than single treatments [40]. In pancreatic tumor
cells, over-expression of cyclin D1 also dramatically re-
duced chemosensitivity and prolonged survival time upon
cisplatin treatment, and knockdown of cyclin D1 resulted
in impaired resistance to cisplatin-induced apoptosis
[41,42]. Moreover, inhibition of cyclin D1 expression in hu-
man pancreatic cancer cells enhances their responsiveness
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including 5-fluorouracil, 5-fluoro-2'-deoxyuridine, and
mitoxantrone [43]These findings demonstrate that up-
regulation of cyclin D1 may be a major reason of
cisplatin resistance in multiple tumors. In this regard,
cyclin D1 could be a potential marker for treatment
evaluation and a candidate target to improve the treat-
ment of cisplatin-resistant tumors. Our study indicated
that Let-7b might down-regulate cyclin D1 protein ex-
pression through targeting its 3’-UTR. Therefore, cyclin
D1 down-regulation induced by restoration of Let-7 in
tumors might be a novel therapeutic strategy for cisplatin-
resistant glioblastoma treatment.
To sum up, we generated a cisplatin-resistant glio-
blastoma cell line U251R, and analyzed miRNA expres-
sion profiles in U251R compared with its parental cell
line U251. Microarray data indicated that Let-7b was
dramatically down-regulated in U251R cells compared
with U251 cells. Furthermore, ectopic expression of Let-
7b remarkably inhibited U251R cell chemoresistance to
cisplatin through cyclin D1 expression blockade. Cyclin
D1 knockdown significantly promoted cisplatin-induced
apoptosis and G1 arrest. In conclusion, Let-7b could be
considered as a novel marker of cisplatin resistance dur-
ing early diagnosis, and more importantly, restoration of
Let-7 in tumor cells could offer a novel therapeutic ap-
proach for cisplatin-resistant glioblastoma treatment.
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